---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-24-004200"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:38:38.142104+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Alzamend Neuro files amended Series B preferred stock designation and eliminates Series A

## Summary
- Filed amended and restated certificate of designations for Series B preferred stock on March 1, 2024.
- Amendment corrects references from Series A to Series B and clarifies voting rights per Nasdaq rules.
- Filed certificate of elimination to remove Series A convertible preferred stock from charter, effective March 1, 2024.
- No changes to preferences and rights of Series B beyond the correction and clarification.
- All actions are procedural with no financial or operational impact disclosed.

## SEC filing metadata
- accession: 0001214659-24-004200
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465924004200/0001214659-24-004200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465924004200/g362408k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-24-004200
- JSON: https://secwatch.observer/filing/0001214659-24-004200.json
- Plain text: https://secwatch.observer/filing/0001214659-24-004200.txt

## Key facts
- Governance Changes
  Alzamend Neuro, Inc.: Filed Certificate of Elimination for Series A Convertible Preferred Stock, removing its designation from the Certificate of Incorporation (effective 2024-03-01).
  - Change: charter amendment
  - Effective: 2024-03-01
  source text: on March 1, 2024, the Company filed with the Secretary of State of the state of Delaware, a Certificate of Elimination of the Certificate of Designations of Preferred Stock of Alzamend Neuro, Inc. (the “ Certificate of Elimination ”), with respect to the Company’s Series A convertible preferred stock, par value $0.0001 per share (“ Series A Convertible Preferred Stock ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1677077/000121465924004200/0001214659-24-004200-index.htm
- Governance Changes
  Alzamend Neuro, Inc.: Filed Amended and Restated Certificate of Designations for Series B Preferred Stock to correct references and clarify voting rights (effective 2024-03-01).
  - Change: charter amendment
  - Effective: 2024-03-01
  source text: On March 1, 2024, the Company filed with the Secretary of State of the state of Delaware an Amended and Restated Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the “ Amended and Restated Certificate of Designations ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1677077/000121465924004200/0001214659-24-004200-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.